



Key Indices Update

Indices	Close	Change (%)
Nifty	23227.80	0.22 🗷
Sensex	76724.08	0.29 7
Midcap	53905.80	0.43 7
Smallcap	17345.15	0.51 7

Trend Strength Indicator

Nifty 50 Stocks above	NSE Advance /
200 EMA	Decline
17	1535 /1252

Key Data

Data	Current	Previous
Dow Jones	43,330.6	42,606.6
U.S. Dollar Index	108.98	109.25
Brent Crude (USD/BBL)	82.21	80.03
US 10Y Bond Yield (%)	4.66	4.79
India 10Y Bond Yield (%)	6.85	6.80

Sectoral Data

Sector	Close	Change (%)
BANKNIFTY	48779.20	0.10 🗷
NIFTYAUTO	22720.15	ע 9.49
NIFTYENERGY	33844.55	0.82 🗷
NIFTYFINSRV	24508.05	0.02 🗷
NIFTYFMCG	55560.90	ע 0.12
NIFTYIT	43423.30	0.84 7
NIFTYMEDIA	1690.75	וא 1.35
NIFTYMETAL	8278.25	0.13 7
NIFTYPHARMA	21960.30	וו 1.10
NIFTYREALTY	919.60	1.26 7

JANUARY 16, **2025**

Fundamental

Refer Page 02

Stock for Investment

Stock Name	Sector	*CMP (₹)	^TP (₹)	Upside
NCC	Infrastructure	243	340	39.6%

*CMP as on Jan. 15, 2025

Top News

- + HDFC Life Insurance reported strong 9M FY25 results: 24% growth in individual APE, 14% growth in Value of New Business, and 15% growth in Profit After Tax.
- + Angel One Limited's Q3 and nine-month results ending Dec 31, 2024, show total revenue of ₹12,637.96M and a profit before tax of ₹3,873.28M.

Technical

Refer Page 03-04

- + NIFTY traded in a subdued manner and ended marginally higher, extending Tuesday's trend.
- + Sector-wise, a mixed performance continued, with **gains in** realty, IT, and energy, while pharma and auto sectors closed in the red.
- + Traders should align their strategies with a **strong focus on risk** management.
- + Stock of the day DRREDDY.





Fundamental

Top News

01

Antony Waste Handling Cell Limited delivered **strong Q3 & 9M FY25 results**. Managed 0.49M tonnes and processed 0.69M tonnes of MSW. PCMC Waste-to-Energy facility hit a 77% Plant Load Factor.

02

Shalby Limited's subsidiary, Shalby Advanced Technologies Inc., USA, has received U.S. FDA 510(k) clearance for its Primary Total Knee Replacement device, DuraniomTM, with TiNbN coating, on January 14, 2025.

03

Exide Industries has **invested Rs. 149.99** crore in its wholly owned subsidiary, Exide Energy Solutions, which manufactures lithium-ion battery cells, modules, and packs for EVs and stationary applications, maintaining 100% ownership.

04

HDFC Life Insurance reported strong 9M FY25 results: 24% growth in individual APE, 14% growth in Value of New Business, and 15% growth in Profit After Tax.

05

Angel One Limited's Q3 and nine-month results ending Dec 31, 2024, show total revenue of ₹12,637.96M and a profit before tax of ₹3,873.28M.

Stock for Investment

NCC Ltd.

Stock Symbol	NCC
Sector	Infrastructure
*CMP (₹)	243
^Target Price (₹)	340
Upside	39.6%

- NCC Limited is one of India's leading construction and infrastructure companies. It operates across diverse sectors such as buildings, roads, water supply, power, irrigation, and real estate. NCC is known for executing large-scale projects, including airports, highways, and urban infrastructure. The company has a strong domestic presence and a growing international footprint, particularly in the Middle East.
- + NCC has a **robust and diversified order book**, which stood at ₹**52,370 crore** as of September 2024. The company has a **strong order pipeline of more than ₹2,10,000 crore** and is **targeting a minimum of ₹20,000 crore in new orders for FY25.**
- + NCC has strategically expanded its portfolio by entering the promising smart metering sector, aligning with India's push for digital infrastructure and energy efficiency. Smart metering, a key component of government initiatives like the Smart Cities Mission and the Revamped Distribution Sector Scheme (RDSS), offers significant growth potential. NCC has secured three major smart metering projects worth ₹8,080 crore.
- + NCC Ltd. is well-positioned to benefit from the ongoing capex upcycle. As a leading player in the construction and infrastructure sector, NCC stands to gain from the increased allocation to infrastructure projects, particularly in railways, roads and urban development.
- Financially, we expect its revenue/EBITDA/PAT at a CAGR of 14%/20%/29% over FY24-27E and have initiated coverage on NCC Limited with a Buy rating and a target price of Rs 340.

*CMP as on Jan. 15, 2025 ^Time horizon - upto 11 Months





Technical

Consolidation continues but tone negative, Reduce positions on bounce.

NIFTY	S1	\$2	RI	R2
23227.80 🗷 51.75 (0.22%)	23050	22900	23340	23500



- NIFTY traded in a subdued manner and ended marginally higher, extending Tuesday's trend.
- Sector-wise, a mixed performance continued, with gains in realty, IT, and energy, while pharma and auto sectors closed in the red.
- + Immediate trading resistance stays at 23340.
- Traders should align their strategies with a strong focus on risk management.

BANKNIFTY	S1	S2	R1	R2
48779.20 7 50.05 (0.10%)	48400	47900	49350	49700



- + Bank Nifty opened with a muted stance and traded lacklustre throughout the session.
- + The index is witnessing consolidation post major correction from high levels, closing forming doji on the daily chart.
- Banking majors stayed muted with Kotak Bank and some PSUs posting some short covering.
- + Fresh downside can trigger, post breaking down below the 48400 mark.
- + Traders are recommended to play with a **sell-on-bounce strategy** in the index.





Technical

Stock of the day	Recom.	CMP (₹)	Range*	SL	Target
DRREDDY	BUY	1336.10	1335-1340	1290	1430



- + DRREDDY's setup suggests a **steady uptrend.**
- Stock is continuously trading, forming higher highs and higher lows, and inching higher, taking support at important weekly moving averages.
- + Expect the stock to continue its primary trend, i.e., bullish. Maintain buy on DRREDDY with a support of 1290.
- Traders are recommended to accumulate the stock for a gradual up move towards the 1430 mark.

Name	Price	Price %
UTIAMC	1259.90	6.43 🗷
DEVYANI	189.00	6.00 🗷
WELCORP	761.90	4.21 7
ABSLAMC	769.75	4.20 🗷
NAM-INDIA	661.05	4.00 7

Name	Price	Price %	
BATAINDIA	1310.00	لا 2.50	Range Bre
GRANULES	571.05	2.18 🗵	eak Peak
AUROPHARMA	1149.00	צ 2.17	je Breakov eakdown
-	-	-	n out/
-	-	-	

r	
S	
Gainers A	
5 F&O	
	ĺ
<u>6</u>	

Name	Price	Price %
BSE	5781.10	6.10 🗷
IDEA	8.75	6.06 🗷
ANGELONE	2494.85	5.24 7
LTF	140.71	5.22 🗷
ZOMATO	245.70	5.18 🗷

Name	Price	Price %	-
KALYANKJIL	550.00	لا 7.78	7
CGPOWER	609.50	ע 4.79	ģ
MAXHEALTH	1041.00	4.05 🗵	
M&M	2961.00	لا 2.90	בסמפוט
DIVISLAB	5835.00	لا 2.59	Ŀ

ts
ō
5
ي
≝
Bu

Name	Price	Price %
BSE	5781.10	6.10 🗷
ZOMATO	245.70	5.18 🗷
PAYTM	855.00	4.54 7
MCX	5950.00	4.50 🗷
INDHOTEL	813.00	4.04 7

Name	Price	Price %	
AXISBANK	1025.00	لا 2.53	ם מנו
BATAINDIA	1310.00	2.50 كا	
NATIONALUM	194.55	2.49 צ	
HINDCOPPER	220.89	צ 2.30	5
CUMMINSIND	2876.85	لا 2.18	





Research Team

Name	Email ID
Ajit Mishra	ajit.mishra@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Ashwani Harit	ashwani.harit@religare.com
Divya Parmar	divya.parmar@religare.com
Vinay Kalani	vinay.kalani1@religare.com
Aniket Varshney	aniket.varshney@religare.com





Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: https://www.religareonline.com/disclaimer

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation—Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under $F(\alpha)$ to F(j) below, are given separately]:

S. No.	Statement		Answer	
		Yes	No	
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No	
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No	
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?	at		
	I/we have received any compensation from the subject company in the past twelve months?		No	
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No	
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No	
	I/we have served as an officer, director or employee of the subject company?		No	
	I/we have been engaged in market making activity for the subject company?		No	

Nature of Interest if answer to F(a) above is Yes:	Name(s) with Signature(s) of RA(s)

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results